A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability

Dr. Barber holds stock in AbbVie, Bristol-Myers Squibb, Danaher Corporation, Eli Lilly, Johnson & Johnson, and UnitedHealth Group. Dr. Nemeroff has served as a consultant for Acadia Pharmaceuticals, Alfasigma, ANeuroTech (division of Anima BV), BioXcel Therapeutics, Clexio, Corcept Therapeutics, EcoR1, EMA Wellness, Engrail Therapeutics, GoodCap Pharmaceuticals, Intra-Cellular Therapies, Magstim, Navitor Pharmaceuticals, Neuritek, Pasithea Therapeutics, Sage, Senseye, Signant Health, Silo Pharma, SK Life Science, and XW Pharma; he has served on scientific advisory boards for the Anxiety and Depression Association of America (ADAA), ANeuroTech, the Brain and Behavior Research Foundation, Heading Health, the Laureate Institute for Brain Research, Magnolia CNS, Pasithea Therapeutics, Sage, Signant Health, Skyland Trail, and TRUUST Neuroimaging, and on the boards of directors of ADAA, Gratitude America, Lucy Scientific Discovery, and Xhale Smart; he holds stock in Antares, BI Gen Holdings, Corcept Therapeutics, EMA Wellness, Naki Health, Seattle Genetics, TRUUST Neuroimaging, and Xhale; and he is named on U.S. patents 6,375,990B1 and 7,148,027B2. Dr. Siegel has received research grants from Astellas and NIH; he has served as a consultant for Zynerba and as an advisory board member for Skyland Trail; and he is named on Australian patents 2005206143, 2006269927, and 2006269927; European patents 2010184 and 2633853; Israeli patent 194506; Korean patents 10-1197540 and 10-1283946; Japanese patent 5306599; Canadian patents 2553254 and 2,614,601; and U.S. patents 7,666,445, 8,221,778, 8,329,203, 8,475,830, 8,475,829, 8,741,327, 8,802,127, 8,758,795, 10-736,965 B2, and 2019/0105396 A1.